SUMMARY In a prospective study, 161 infants with neonatal tetanus were randomised to receive (a) standard treatment, or (b) standard treatment together with intrathecal equine antitetanus serum, or (c) intrathecal antitetanus serum with systemic betamethasone. There was no difference in survival between the three treatment groups in infants with severe tetanus, but in mild tetanus those who received standard treatment alone had an improved survival rate. Parenteral intramuscular diazepam as a sedative was found to be preferable to paraldehyde, as the latter was associated with a higher incidence of secondary infections.
Neonatal tetanus is still a major cause of neonatal death in many countries, with reported mortality in patients in hospital ranging between 55 and 86%.1 Management in many such countries consists of administration of equine antitetanus serum (ATS) or human tetanus hyperimmune globulin (TIGH) in combination with sedatives and antibiotics, as resources and staff are generally not available for mechanical respiratory support.
In recent years there has been a revival of interest in the use of intrathecally-administered ATS. Its use was abandoned in the 1940s owing to the high incidence of complications,2 but recent reports have shown that combined with steroids it can be given safely. Initial studies reported favourably on the use of either intrathecal ATS or TIGH. [3] [4] In an effort to reduce the high mortality rate associated with neonatal tetanus, we decided to evaluate intrathecal ATS as an adjunct to our standard treatment in a controlled study. We hoped that this might be a useful and easy adjunct to treatment, even in small rural hospitals. Intrathecal ATS administration was unsuccessful in 4 infants owing to technical problems, and these 4 were eliminated from the study. 276 Failure of intrathecal antitetanus serum to improve survival in neonatal tetanus 277
Results
Each neonate was allocated sequentially to a treatment group-A, B, or C. The mean age on admission was 8-6 days in group A, 7 4 days in group B, and 8 *2 days in group C. The mean weights on admission were 3 2 kg in group A, 3.5 kg in group B, and 3-1 kg in group C. There was no difference in the distribution of genders. The incubation period was measured as the time from the cutting of the umbilical cord until the time of the first symptoms, and was 6.6 days in group A, 6.4 days in group B, and 7-0 days in group C. Thus the patients in each group were similar with regard to age on admission, weight, gender, and incubation period of the disease. The time between the onset of symptoms and admission to hospital also showed no difference between the groups. In group A this was 1.6 days, in group B 1-3 days, and in group C 1 *5 days.
Of the 161 neonates with tetanus 120 (74.5%) were clinically classified as severe and 41 (25.5%) as mild to moderate. The overall survival of both severely and mildly affected groups was 35.4 %. However, the survival rate in the severely affected neonates was low, 16.2% in group A, 21.5% in group B, and 15.6% in group C. The difference in survival between the three groups was not statistically significant (Table 1) .
In the neonates presenting with mild to moderate tetanus, survival of those who received the standard treatment alone (group A) was significantly better (94.7%) than that of those in group B, which was 70% (P<0.05). Survival of group A patients was also better than that of patients in group C (83 -3 %.) but the difference was not significant ( 
